Keyphrases
Combination Therapy
100%
Docetaxel
100%
Castration-resistant Prostate Cancer
100%
Phase II Trial
20%
Improved Outcomes
10%
Clinical Trials
10%
Hormone Therapy
10%
Chemotherapy
10%
Vitamin D Analogs
10%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
10%
Tumor Survival
10%
Search Terms
10%
Antiangiogenic Agents
10%
Phase II Study
10%
Prostate
10%
Tyrosine Kinase Inhibitor
10%
Prostate-specific Antigen Response
10%
Lenalidomide
10%
Tumor Response
10%
Bevacizumab
10%
Bisphosphonates
10%
Radiopharmaceuticals
10%
Bcl-2 Inhibitor
10%
Dasatinib
10%
Conference Abstracts
10%
Doublet Therapy
10%
Aflibercept
10%
Zibotentan
10%
Atrasentan
10%
Castration Resistance
10%
Bone-targeting Agents
10%
Clinical Conference
10%
Pharmacology, Toxicology and Pharmaceutical Science
Combination Therapy
100%
Castration Resistant Prostate Cancer
100%
Docetaxel
100%
Phase III Trials
20%
Neoplasm
10%
Clinical Trial
10%
Chemotherapy
10%
Vitamin D Analog
10%
Protein Tyrosine Kinase Inhibitor
10%
Prostate Cancer
10%
Prostate Specific Antigen
10%
Endocrine Therapy
10%
Lenalidomide
10%
Bevacizumab
10%
Bisphosphonic Acid Derivative
10%
Angiogenesis Inhibitor
10%
Dasatinib
10%
Aflibercept
10%
Immunologic Agent
10%
Zibotentan
10%
Atrasentan
10%